Promising results from an early-stage trial suggest that lenacapavir injections might offer long-lasting protection.
The Canadian Press on MSN1d
TPH saw ‘many deviations’ at gynecologist’s clinic with potential HIV, hepatitis exposureToronto Public Health says it observed “many deviations from best practices” during an inspection at the gynecologist's ...
Health and Me on MSN2d
Yearly Jab For HIV Protection Is Now Almost HereA yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
Baystate Wing Hospital in Palmer, Mass., has contacted an unknown number of patients who may have been exposed to hepatitis or HIV due to a potential sterilization issue during surgeries performed ...
The Canadian Press on MSN5d
Potential HIV, hepatitis exposure at Toronto gynecology clinic has patients worriedThe letter said patients who received endometrial biopsies, IUD insertions or had cervical growths removed at the clinic ...
Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...
HIV self-testing remains underutilized among not only the general public, but especially people who use drugs.
HIV prevention has advanced with lenacapavir, a yearly injection that blocks the virus's replication, providing long-term ...
Already, significant harm has been done to inhibit progress combating HIV/AIDS, and the next four years could return us to ...
Phase I trial results show the potential of once-yearly lenacapavir as a long-acting PrEP option for HIV, supporting further ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback